•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a pharmaceutical company focused on late-stage development and registration of ZEPIZURE®, its emergency solution for managing epilepsy crises, has made its annual financial report 2025 available to the public and filed it with the Autorité des Marchés Financiers.
The company announced that the 2025 annual financial report has been made available to the public and submitted to the French financial markets regulator. The report can be consulted on CROSSJECT’s website.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
